Assessing Generalizability of the Findings from EXCEL and NOBLE; Comparison with IRIS-MAIN Registry


Duk-Woo Park, MD, PhD

Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea





Data for Left Main 20 years ago




PTCA was not considered as an Tx option









TCTAP 2017

Lee, P.H. et al. J Am Coll Cardiol. 2016;68(11):1233-46.

COVRE


Comparisons of PCI against CABG In 2nd DES era, finally released

	Design	N (PCI/ CABG)	Sites	Recruitment period	Endpoint	FU, yrs	Stent type used for PCI
NOBLE	Multicenter RCT, non- inferiority	598/603	36 sites in northern Europe	Dec 2008 –Jan 2015	All-cause death, non- procedural MI, RR, or stroke	3.1 (2.0-5.0)	BioMatrix BES
EXCEL	Multicenter RCT, non- inferiority	948/957	126 sites in North/South America, Europe, AP	Sep 2010 −Mar 2014	All cause death, MI, or stroke	3.0 (2.4-3.0)	Xience EES

Interesting similarities and differences Impact on practice Beyond 2016?









Follow-up: 1 month, 6 months, 1 year, annually through 5 years **Primary endpoint:** Measured at a median 3-yr FU, minimum 2-yr FU










Lancet 2016



NOBLE Death, non-procedural MI, Stroke, or RR



TCTAP2017

Lancet 2016



EXCEL vs. NOBLE Trial

Variables	EXCEL	NOBLE
Number of patients	1,905	1,201
Median follow-up	3 year	3.1 year

IR(95%CI), CABG/PCI		
rimary endpoint	1.0 (0.79-1.26)	1.48 (1.11-1.96)
All-cause death	1.34 (0.94-1.91)	1.07 (0.67-1.72)
Cardiac death	1.18 (0.74-1.87)	0.93 (0.45-1.92)
1	0.93 (0.67-1.28)	2.88 (1.40-5.90)
troke	0.77 (0.43-1.37)	2.25 (0.93-5.48)
evascularization	1.72 (1.27-2.33)	1.50 (1.04-2.17)

Η

Ρ

A

C

N

S

R

NOBLE: Stent thrombosis (3% NOBLE vs. 0.7% EXCEL), stroke (HR 2.25, p=0.07), non-procedural MI excluded (7% CABG vs. 5% PCI)

COVRE

Our Aim and Study Population

- To understand the similarities and differences, and assess the generalizability of EXCEL and NOBLE trial in real world setting.
- The IRIS MAIN registry is a nonrandomized, multi-national, multicenter observational study to assess the practice and outcomes of LM disease.
- All-comers design, consecutive patients with LM disease treated with medical Rx, PCI, or CABG



Left Main Coronary Artery Disease



Secular Trends in Patient Characteristics, Treatments, and Outcomes

Pil Hyung Lee, MD,^a Jung-Min Ahn, MD,^a Mineok Chang, MD,^a Seunghee Baek, PHD,^b Sung-Han Yoon, MD,^a Soo-Jin Kang, MD, PHD,^a Seung-Whan Lee, MD, PHD,^a Young-Hak Kim, MD, PHD,^a Cheol Whan Lee, MD, PHD,^a Seong-Wook Park, MD, PHD,^a Duk-Woo Park, MD, PHD,^a Seung-Jung Park, MD, PHD^a

ABSTRACT

Left main coronary artery (LMCA) disease is the highest-risk lesion subset of ischemic heart disease, and has traditionally been an indication for coronary artery bypass grafting (CABG). Recent evidence suggests comparable clinical outcomes between percutaneous coronary intervention (PCI) and CABG for LMCA disease, with similar rates of mortality and serious composite outcomes, a higher rate of stroke with CABG, and a higher rate of repeat revascularization with PCI. These results have been translated to the current guideline recommendation that PCI is a reasonable alternative to CABG in patients with low to intermediate anatomic complexity. However, how the characteristics, treatment, and clinical outcomes of patients with unprotected LMCA disease have evolved over time has not yet been fully evaluated. We therefore described secular trends in the characteristics and long-term outcomes of unprotected LMCA disease using "real-world" clinical experience from the IRIS-MAIN (Interventional Research Incorporation Society-Left MAIN Revascularization) registry together with a broad review of this topic. (J Am Coll Cardiol 2016;68:1233-46) © 2016 by the American College of Cardiology Foundation.



CVRF

IRIS-MAIN Registry

 Between January 1995 and December 2013, a total of 5833 patients were enrolled from 50 academic and community hospitals in Asia (China, India, Indonesia, Japan, Malaysia, South Korea, Taiwan, and Thailand).

Three time periods

- Wave 1 (BMS) for 1995–2002
- Wave 2 (First G DES) for 2003–2006
- Wave 3 (Second G DES) for 2007–2013





Comparative Outcomes and Definitions

Outcomes for between – study comparison

- Composite of death, MI, or stroke 1 endpoint of EXCEL
- MACCE (death, MI, stroke, or RR) 1 endpoint of NOBLE

Different definitions of MI between studies

- **EXCEL:** Procedure related MI (any elevation of CK-MB >10 times URL, or >5 times plus evidence of ischemia), and sponMI (CK-MB or troponin >URL with evidence of ischemia)
- **NOBLE:** <u>only non-procedural MI</u> (*increase in CK-MB or troponin >URL with ischemic symptoms or signs*)
- **IRIS-MAIN:** Procedural related MI (CK-MB >5times URL plus evidence of ischemia), sponMI (CK-MB >URL with ischemic Sx or signs)

Baseline Characteristics

	PCI Cohort				CABG Cohort			
	EXCEL (n=948)	NOBLE (n=592)	IRIS-MAIN (2 nd DES) (n=1,707)	IRIS-MAIN (1 st DES) (n=1,055)	EXCEL (n=957)	NOBLE (n=592)	IRIS-MAIN (2 nd DES) (n=774)	IRIS-MAIN (1 st DES) (n=964)
Age, yrs	66.0	66.2	64.4	62.4	65.9	66.2	65.2	63.7
Male sex, %	76.2	80.4	77.7	72.8	77.5	76.4	79.6	74.4
BMI, kg/m ²	28.6	27.9	24.5	24.5	28.8	28.1	24.5	24.5
DM, %	30.2	14.5	33.7	33.4	28.0	15.2	42.2	38.4
HTN, %	74.5	65.2	63.8	55.7	73.9	65.7	66.7	54.8
Current smoker, %	24.1	18.2	23.8	25.1	20.8	21.4	26.6	27.2
HL, %	71.5	81.5	49.0	37.8	69.3	78.4	52.5	34.6
Previous MI, %	18.1	NA	6.6	8.8	16.9	NA	11.5	13.3
Previous stroke, %	5.5	NA	8.7	7.9	7.0	NA	9.2	7.0
Previous PCI, %	18.4	19.6	15.4	19.9	15.9	19.9	12.9	12.3
Previous HF, %	7.1	NA	2.6	2.4	6.2	NA	3.1	3.8
PVD, %	10.3	NA	4.5	2.8	8.8	NA	7.1	7.1
CLD, %	6.9	NA	2.4	2.7	8.5	NA	3.4	3.6
CKD*, %	17.6	NA	4.4	2.9	15.4	NA	4.9	3.5

Baseline Characteristics

	PCI Cohort				CABG Cohort			
	EXCEL (n=948)	NOBLE (n=592)	IRIS-MAIN (2 nd DES) (n=1,707)	IRIS-MAIN (1 st DES) (n=1,055)	EXCEL (n=957)	NOBLE (n=592)	IRIS-MAIN (2 nd DES) (n=774)	IRIS-MAIN (1 st DES) (n=964)
Clinical indication,%								
Silent/Stable AP	60.8	82.1	40.8	44.2	60.5	82.9	43.5	25.9
ACS	39.2	17.9	59.2	55.8	39.5	16.9	56.5	74.1
Mean LVEF, %	57.0	60	59.0	60.2	57.3	60	55.3	56.4
Disease extent, %								
LM only	17.3	NA	10.8	13.8	17.8	NA	2.7	3.4
LM plus 1VD	31.0	NA	25.8	22.2	31.2	NA	5.8	8.4
LM plus 2VD	34.5	NA	36.3	31.2	31.5	NA	20.0	21.9
LM plus 3VD	17.2	NA	27.1	32.8	19.4	NA	71.4	66.3
LM location, %								
Ostium or shaft	18.2	19.4	33.0	43.1	20.8	18.6	27.5	36.5
Distal bifurcation	81.8	80.6	67.0	56.9	79.2	81.4	72.5	63.5
Right CAD, %	NA	NA	41.1	43.8	NA	NA	80.4	76.2
SYNTAX score	20.6	22.5	NA	NA		20.5	22.4	NA

TCTAP 2017

PCI characteristics PCI cohort


	EXCEL (n=935)	NOBLE (n=580)	IRIS MAIN (2 nd DES) (n=1,707)	IRIS MAIN (1 st DES) (n=1,055)
Stent technique, %				
Left main stenting only or simple crossover	NA	69.7	78.0	76.1
Two-stent technique	NA	31.4	22.0	23.9
Final kissing balloon	NA	54.5	29.7	38.5
Total stent number per patient	2.4±1.5	2 (IQR; NA)	2.2±1.2	2.2±1.3
Stent number in LMCA	NA	1 (IQR 1–2)	1.7±0.9	1.5±0.8
Total stent length per patient	49.1±35.6	52 (IQR; NA)	52.3±34.1	45.5±33.0
IVUS-guided PCI, %	77.2	74.1	76.7	78.9
Hemodynamic support, %	5.2	NA	5.0	3.5
DES type, %				
CoCr-EES	98.4	_	36.7	-
BES	—	89.1	8.4	-
PtCr-EES	_	_	22.1	_
Re-ZES	_	_	26.9	_
PC-ZES	_	_	1.9	—
Other 2 nd DES	_	_	4.0	_
SES	_	10.9	_	82.6
PES	_	_	_	17.4


CABG characteristics CABG cohort

	EXCEL (n=923)	NOBLE (n=567)	IRIS MAIN (2 nd DES era) (n=774)	IRIS MAIN (1 st DES era) (n=964)
Off-pump surgery, %	29.4	15.6	69.4	46.2
No. of conduits per patient	2.6±0.8	2.5±0.7	2.9±0.9	2.9±1.0
No. of arterial grafts	1.4±0.6	NA	1.6±0.9	2.2±0.9
No. of vein grafts	1.2±0.9	NA	1.3±1.0	0.7±0.8
Use of internal mammary artery, %	98.8	93.1	94.2	95.3
Use of radial artery, %	6.0	4.8	36.6	61.4



Death, MI, or Stroke Compared with matched cohorts of IRIS-MAIN





TCTAP

CVRF

In Summary...

1. Baseline characteristics and results are relatively similar in EXCEL and in this large registry.

2. With respect to hard clinical endpoint (i.e., death, MI, or stroke), the results of the EXCEL trial and the IRIS-MAIN registry suggest that PCI with contemporary DES is an acceptable alternative to CABG who have clinical equipose for either strategy of revascularization

3. EXCEL seems to be more generalizable than NOBLE in terms of patient inclusion and outcomes.



Issues within Studies and limitations

1. NOBLE;

- 11% of PCI cohort received 1st generation DES.
- Excluded procedural MI; miss of important myocardial events
- Results extrapolated to a projected 5yr FU; preferentially represents the patient initially recruited
- High rates of stroke in PCI arm
- SYNTAX score did not work

2. EXCEL

- Does procedural MI really matter?
- Catch-up phenomenon of PCI curve at 3 years
- 24% of patients had a core lab defined high SYNTAX score

3. IRIS-MAIN is just one of the real world registry



